MolNFT v1 · #99725 · protein
HIV protease in complex with SA526P
4MC1: “HIV protease in complex with SA526P”. X-ray diffraction, 2 ligands (526, CL), 1 pocket (best druggability 0.75). MolNFT v1 #99725 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 4MC1
- Type
- protein
- Length
- 198 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Protease
- EC
- 3.4.23.16
- UniProt
- P0C6F2
- Ligands
- 526, CL
- Pockets
- 1 · best druggability 0.75
Structure
x-ray diffraction · 1 distinct chain · 4% helix, 56% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A, B | Protease (EC 3.4.23.16) | protein | 99 | 4% helix, 56% strand | P0C6F2 |
Ligands and binding sites
- 526 · (3S)-tetrahydrofuran-3-yl {(2S,3R)-4-[(4S)-4-tert-butyl-7-fluoro-1,1-dioxido-4,5-dihydro-1,2-benzothiazepin-2(3H)-yl]-3-hydroxy-1-phenylbutan-2-yl}carbamate · ligand · 2 copies · chains A, B
- CL · Chloride ion · ion · 3 copies · chains A, B
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 347 | 0.75 | 0.86 | 34 | 526 |
Interfaces
1 interface between chains.
- A–B · 1858 Ų buried · 39 hydrogen bonds · protein-protein
Compared structures
- 4MC1 · HIV protease in complex with SA526P · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P0C6F2
- Elsewhere: RCSB PDB 4MC1 · PDBe 4MC1 · UniProt P0C6F2
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.